How I treat acquired aplastic anemia

Area of Science:

• Hematology
• Immunology

Background:

• Acquired severe aplastic anemia (SAA) is a rare, life-threatening hematologic disorder.
• Immune-mediated destruction of hematopoietic stem cells is a key pathogenic mechanism in SAA.

Purpose of the Study:

• To review current therapeutic strategies for acquired severe aplastic anemia.
• To highlight the importance of patient age and early intervention in treatment outcomes.

Main Methods:

• Review of current literature on SAA treatment options.
• Discussion of immunosuppressive therapy (IST) and bone marrow transplantation (BMT).

Main Results:

• IST can lead to transfusion independence or recovery in some SAA patients.
• BMT offers a curative option, with matched sibling donors being optimal.
• Graft-versus-host disease is a significant complication of BMT.
• Late clonal disorders can arise following IST.

Conclusions:

• Both IST and BMT are viable treatment options for SAA.
• Patient age is a critical factor influencing outcomes for both IST and BMT.
• Early diagnosis, prompt treatment, and long-term monitoring are essential for managing SAA effectively.